Synergistic Activity of Anti-GD2 Antibody and CD47-Blockade for Immunotherapy of Neuroblastoma and Osteosarcoma |
The Board of Trustees of the Leland Stanford Junior University / Robbie Majzner, MD |
'A' Award Grants |
2019 |
California |
Elucidating the Role of SETD2 in Pediatric High Grade Glioma Formation |
Children’s Hospital of Philadelphia / Thomas De Raedt, PhD |
'A' Award Grants |
2019 |
Pennsylvania |
Exploiting the Differentiation Potential of Pediatric High-Grade Glioma to Discover Novel Therapeutic Opportunities |
Dana-Farber Cancer Institute / Mariella Filbin, MD/PhD |
'A' Award Grants |
2019 |
Massachusetts |
The use of hematopoietic stem and progenitor cells to reverse treatment resistance to PD-1 blockade |
University of Florida / Catherine Flores, PhD |
Innovation Grants |
2019 |
Florida |
Identify Novel Druggable Targets to Treat Philadelphia chromosome-like B-Acute Lymphoblastic Leukemia |
Children’s Hospital of Philadelphia / Wei Tong, PhD |
Innovation Grants |
2019 |
Pennsylvania |
Using Splice Switching Oligonucleotides (SSOs) to target MDM2 for rhabdomyosarcoma therapy |
Research Institute at Nationwide Children's Hospital / Dawn Chandler, PhD |
Innovation Grants |
2019 |
Ohio |
Targeting mechanisms of Siglec15-mediated immune evasion in hematologic malignancies |
Emory University / Christopher Porter, MD |
Innovation Grants |
2019 |
Georgia |
The anti-tumor immune microenvironment in the Sonic Hedgehog subclass of medulloblastoma |
Emory University / Anna Kenney, PhD |
Innovation Grants |
2019 |
Georgia |
Therapeutic Targeting of the Disrupted Metabolic State in DIPG |
University of Michigan / Costas Lyssiotis, PhD & Sriram Venneti, MD/PhD |
Innovation Grants |
2019 |
Michigan |
Norepinephrine Transporter-Targeted Pharmacotherapy of Aggressive Neuroblastoma |
Children’s Hospital of Philadelphia / Michael Chorny, PhD |
Innovation Grants |
2019 |
Pennsylvania |